The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.
The cancers can be ordered histologically or alphabetically.
For each cancer, the staining for each available antibody is reported as the fraction of samples with strong, moderate, weak or no staining (as described by the color-coding scale in the box to the right). The lenght of the bar represents the number of patient samples analysed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.
At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the immunohistochemistry validation score for that antibody.
A majority of malignant tissues showed weak to moderate cytoplasmic immunoreactivity. Strong staining was observed in a few cases of endometrial-, ovarian- and testicular cancer.
Most malignancies displayed weak to moderate cytoplasmic and nuclear staining. Rare cases of prostate, ovarian, testis, pancreatic and lung cancers displayed strong staining.
Most of the malignant cells showed weak to moderate nuclear and/or cytoplasmic positivity. Several testicular cancers displayed strong nucleolar immunoreactivity. A majority of
liver, gastric, renal, skin and prostate cancers were negative.
Validation
The multi-targeting antibody yielding a staining pattern partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data for all of the genes
One antibody yielding a staining pattern and there is no available gene/protein characterization data or the staining pattern is partly consistent with or contradicted by limited gene/protein characterization data
The multi-targeting antibody yielding a staining pattern partly consistent with gene/protein characterization data or consistent with limited gene/protein characterization data for all of the genes
